Literature DB >> 12677447

Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study.

Victoria Zhukareva1, Sonali Sundarraj, David Mann, Magnus Sjogren, Kaj Blenow, Christopher M Clark, Daniel W McKeel, Alison Goate, Carol F Lippa, Jean-Paul Vonsattel, John H Growdon, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

Recently, biochemical criteria were proposed to complement histological criteria for the diagnosis of dementia lacking distinctive histopathology (DLDH), the most common pathological variant of frontotemporal dementias (FTDs), based on evidence of a selective reduction of soluble tau proteins in brains from a large cohort of sporadic DLDH and hereditary FTD (HDDD2 family) patients. To ensure that these findings are not unique to the populations included in the initial report, we extended the previous work by analyzing 22 additional DLDH brains from the United States and international centers. Our biochemical analyses here confirmed the previous findings by demonstrating substantial reductions in soluble brain tau in gray and white matter of 14 cases and moderate reductions in 6 cases of DLDH. We also analyzed brain samples from an additional affected HDDD2 family member, and remarkably, unlike other previously studied members of this kindred, this patient's brain contained substantial amounts of pathological or insoluble tau. These findings confirm and extend the definition of DLDH as a sporadic or familial "tau-less" tauopathy with reduced levels of soluble brain tau and no insoluble tau or fibrillary tau inclusions, and the data also underline the phenotypic heterogeneity of HDDD2, which parallels the phenotypic heterogeneity of other hereditary neurodegenerative FTD tauopathies caused by tau gene mutations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12677447     DOI: 10.1007/s00401-002-0668-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  18 in total

1.  Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.

Authors:  Peng Lei; Scott Ayton; David I Finkelstein; Loredana Spoerri; Giuseppe D Ciccotosto; David K Wright; Bruce X W Wong; Paul A Adlard; Robert A Cherny; Linh Q Lam; Blaine R Roberts; Irene Volitakis; Gary F Egan; Catriona A McLean; Roberto Cappai; James A Duce; Ashley I Bush
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Tau missing from CSF: a case report.

Authors:  Antonella Alberici; Mario Armani; Anna Paterlini; Luisa Benussi; Francesca Nicosia; Roberta Ghidoni; Simona Signorini; Maria Cotelli; Giovanni B Frisoni; Cristina Geroldi; Carlo P Trevisan; John H Growdon; Barbara Borroni; Alessandro Padovani; Paolo M Rossini; Giuliano Binetti
Journal:  J Neurol       Date:  2007-02-03       Impact factor: 4.849

3.  Ironing out tau's role in parkinsonism.

Authors:  Jeannette N Stankowski; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2012-02-06       Impact factor: 53.440

4.  Lithium suppression of tau induces brain iron accumulation and neurodegeneration.

Authors:  P Lei; S Ayton; A T Appukuttan; S Moon; J A Duce; I Volitakis; R Cherny; S J Wood; M Greenough; G Berger; C Pantelis; P McGorry; A Yung; D I Finkelstein; A I Bush
Journal:  Mol Psychiatry       Date:  2016-07-12       Impact factor: 15.992

5.  Drosophila Tau Negatively Regulates Translation and Olfactory Long-Term Memory, But Facilitates Footshock Habituation and Cytoskeletal Homeostasis.

Authors:  Katerina Papanikolopoulou; Ilianna G Roussou; Jean Y Gouzi; Martina Samiotaki; George Panayotou; Luca Turin; Efthimios M C Skoulakis
Journal:  J Neurosci       Date:  2019-09-05       Impact factor: 6.167

6.  Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease.

Authors:  Jesper Riise; Niels Plath; Bente Pakkenberg; Anna Parachikova
Journal:  J Neural Transm (Vienna)       Date:  2015-02-14       Impact factor: 3.575

Review 7.  Biometals and their therapeutic implications in Alzheimer's disease.

Authors:  Scott Ayton; Peng Lei; Ashley I Bush
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

8.  Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains.

Authors:  Janet van Eersel; Mian Bi; Yazi D Ke; John R Hodges; John H Xuereb; Gillian C Gregory; Glenda M Halliday; Jürgen Götz; Jillian J Kril; Lars M Ittner
Journal:  J Neural Transm (Vienna)       Date:  2009-08-20       Impact factor: 3.575

9.  Tau Deficiency Down-Regulated Transcription Factor Orthodenticle Homeobox 2 Expression in the Dopaminergic Neurons in Ventral Tegmental Area and Caused No Obvious Motor Deficits in Mice.

Authors:  Xiaolu Tang; Luyan Jiao; Meige Zheng; Yan Yan; Qi Nie; Ting Wu; Xiaomei Wan; Guofeng Zhang; Yonglin Li; Song Wu; Bin Jiang; Huaibin Cai; Pingyi Xu; Jinhai Duan; Xian Lin
Journal:  Neuroscience       Date:  2018-01-11       Impact factor: 3.590

10.  Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.

Authors:  David J Irwin; John Q Trojanowski; Murray Grossman
Journal:  Front Aging Neurosci       Date:  2013-02-21       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.